Internal Standards and Guidelines for CSR

  • ■ Declaration of Conduct (Guideline for Daily Application)

  • ■ Policies
    • (1) Research
      • Human Tissue Research
      • Ethical Considerations in Animal Experimentation
    • (2) Development
    • (3) Procurement
      • Ethics in Procurement
    • (4) The Environment
      • Basic Environmental Policies
    • (5) Safety and Health
      • Basic Safety and Health Policy
    • (6) Corporate Citizenship Activities
      • Sumitomo Pharma's Basic Stance on Social Contribution Activities
      • Guidelines for Collaborations with Patient Groups
    • (7) Compliance
      • Compliance Standard
      • Guidelines Concerning Transparency in Collaborations with Medical Institutions (since April 2019)
      • Guidelines Concerning Transparency in Collaborations with Patient Groups
  • ■ Global Quality Policy (Sumitomo Pharma Group Quality Policy)

■ Declaration of Conduct (Guidelines for Daily Application)

The Declaration of Conduct (Guidelines for Daily Application) brings together the specific conduct we are committed to practicing in our corporate activities, for each of the items in the Declaration of Conduct, which concretely embodies our philosophy. It offers specific conduct guidelines that should be practiced routinely by both officers and employees of the Company, and provides a basis for the whole company to unite in the implementation of CSR activities.

1. Follow through the global slogan "Innovation today, healthier tomorrows."

We constantly pursue self-innovation to deliver innovative products and services with speed so that people around the world can lead healthier and more fulfilling lives.

Specific examples of conduct

  • ① Provision of products, information and services from the customer perspective
    • We implement business activities to place the customer first.
    • We develop and promote high quality products.
    • We appropriately support the customers.
  • ② Assess and reflect customer needs
    • We aim to satisfy unmet medical needs for patients and caregivers.
    • We determine and address customers' needs.

2. Pursue trustworthy corporate activities.

We comply with laws and regulations, and conduct transparent and fair corporate activities with the highest level of ethics.
We resolutely sever all relations with antisocial forces and organizations that pose a threat to the order and security of civil society.

Specific examples of conduct

  • ① Fair and transparent corporate activities
    • We operate business activities fairly and transparently.
    • We maintain accurate records and financial controls.
    • We compete fairly. We do not bribe or pay kickbacks.
    • We never do business with antisocial forces and organizations that pose a threat to the order and security of civil society.
  • ② Handling of compliance violations
    • We speak up when we realize we've made a mistake or taken actions that violate our Declaration of Conduct, our policies, or the law.
  • ③ Promotion of appropriate use and provision of safety information
    • We aim to prevent unpleasant cases from happening with our products' quality and safety
    • We report and distribute correct information immediately in case of inadequate product quality and/or a safety issue.
  • ④ Respect of the rights of third parties
    • We fairly obtain information from third party.
    • We respect third party's intellectual property and copyright.

3. Positively disclose and properly manage information.

We disclose corporate information in a timely and appropriate manner.
We take appropriate measures to protect and manage personal and customer information acquired through corporate activities.

Specific examples of conduct

  • ① Appropriate information disclosure
    • We report and distribute correct information immediately in case of inadequate product quality and/or a safety issue.
    • We report information appropriately obtained through business activity.
    • We obtain approval by appropriate divisions before the disclosure.
  • ② Appropriate information management and protection
    • We do not utilize personal information of customers, partners and employees for something other than the entered purpose.
    • We fairly obtain personal information and customers' information.
    • We responsibly manage and protect personal information, customers' information, technical and business information to prevent this information from being leaked or altered.
    • We appropriately manage confidential information before the disclosure.

4. Improve individual capabilities and collaborate with peers.

We work together with respects for diversity, character and personality of peers in an effort to create a healthy and safe work environment.
We focus on doing our best work as we strive for results in an organization that provides opportunities to grow and develop new skills.

Specific examples of conduct

  • ① Creating a workplace environment in which employees can focus on their work with a sense of security
    • We keep our work environment safe.
    • We value satisfaction in the work environment.
  • ② Emphasis on the exercise and cultivation of abilities
    • We value each other's diversity, character and personality in working together.
    • The Company and its managers create opportunities for employees to develop their skills and for personal growth, and do their best to evaluate employees fairly and transparently.
    • Employees make efforts toward self-improvement and through their work, enhance their skills and manifest them in achieving results.
  • ③ Emphasis on autonomy, initiative and creativity
    • We always be brave and take challenges independently.
    • We cultivate our assets to achieve goals.
    • We value dialogue and listen to various opinions conscientiously.
  • ④ Creation of a workplace culture with integrity
    • We draw the line between business and private affairs.
    • We speak up to supervisors immediately in case of a potential problem.

5. Respect human rights.

We respect the rights of all people associated with our company in conducting corporate activities.
We seek ways to work with our business partners, including suppliers, and other relevant stakeholders to promote respect for human rights.

Specific examples of conduct

  • ① Elimination of all discriminatory words and actions
    • We do not tolerate any form of discrimination or harassment, either within or outside the Company, such as that based on race, nationality, ethnicity, gender, age, religion, faith, belief, sexual orientation, gender identity (LGBTQ), academic background, disability, disease, form of employment, or profession.
    • We do not tolerate any form of harassment including sexual harassment and power harassment in the workplace.
  • ② Elimination of discrimination in the workplace
    • We respect the human rights described in the Universal Declaration of Human Rights and the International Labour Organization (ILO)'s core labor standards and the rights of all people associated with our company in conducting corporate activities.
    • We respect human rights, including freedom of association and the right to collective bargaining, prevention of child and forced labor, discrimination with respect to employment and occupation in conducting corporate activities including our business counterparts.
    • We encourage business partners including suppliers and other stakeholders to respect human rights.

6. Positively address global environmental issues.

We positively initiate measures in acknowledgment of environmental issues, which are common challenges to humanity and important requirements for sustained corporate growth.

Specific examples of conduct

  • ① Build environmental awareness
    • We independently address global environmental issues as important requirements.
    • We closely monitor environmental issues including climate change and energy.
  • ② Efficient use of resources and energy
    • We implement measures for the conservation of resources.
    • We value effective use of water and the recycling of waste materials.
  • ③ Environmental activities at home
    • We independently make efforts to address global environmental issues at home.

7. Build harmonious relationships with society.

We value communications with all of our stakeholders and promote initiatives contributing to the realization of a sustainable society.
We conduct business by taking into consideration the local culture and customs of the countries and regions, and contribute toward the development of the local economy and society.

Specific examples of conduct

  • ① Communication with society
    • We value promoting dialogue with broad stakeholders.
    • We pay attention to social demands and feedback our action.
  • ② Appropriate behavior as member of society, corporate citizen
    • Always think about the impact of our behaviors on society.
    • Our words and actions should not go against public decency or social norms, either in the workplace or outside work.
  • ③ Engagement with local communities
    • Value communication with local communities.
    • Contribute to development of local communities through corporate activities.
  • ④ Active Involvement with Communities
    • Actively engage in social contribution activities and volunteer activities.
    • Maintain a great interest in the life of communities.
    • Since we are a company in the life sciences industry, we will make efforts toward achieving healthy lifestyles, and maintain a high level of interest in health-related issues such as prevention and early discovery of diseases, healthcare programs and other policies and disease outbreaks in other countries.

■ CSR Policies and Approach

(1) Research

Human Tissue Research

Our mission is to create excellent medicines that help people around the world live healthier and more fulfilling lives, and we use cutting-edge science and technology to accomplish this. We have established an R&D system designed to drive daily progress on our goal of providing society with much-anticipated medicines as quickly as possible.

Science and technology related to the life sciences have made remarkable progress in recent years. By using the decoded human genome and advanced technology exemplified by the production of induced pluripotent stem cells (iPS cells), scientists have made it possible to reveal the causes of disease and the mechanisms of action of medicines previously unknown. This technological progress is also leading to profound changes in the process of R&D.

The use of human tissues (refers to blood, bodily fluids, tissue, cells, excrement taken from humans and the DNA, etc. extracted from them; includes human ES cells and human iPS cells) has also made it possible to elucidate the phenomena in human body which are undiscoverable in animals. The conventional approach was to use animal models to predict a drug's efficacy and adverse reactions, followed by assessment in clinical trials. Recently, by using human tissues in addition to animal models, researchers are able to develop more effective medicines with a clear mechanism of action and fewer adverse reactions.

Research using human tissues is therefore becoming essential in the creation of excellent medicines. On the other hand, it requires special ethical considerations. For this reason, we established the Rules for the Research Ethics Committee on July 15, 2016. The rules require ethical considerations including paying due consideration to human dignity, giving sufficient explanation in advance to the providers of human tissues and obtaining their voluntary agreement (i.e., informed consent), rigorously protecting personal information, and fairly reviewing the research plan (e.g., the significance and necessity of using human tissues and the potential degree of social contribution of the research).

We have been reviewing research plans in accordance with these rules, in advance of each research project using human tissues. We have also established written standards for ethics review and made public the Rules for the Research Ethics Committee and the membership of the committee.

Click here to see the Research Ethics Committee page in the "R&D" section for details.(in Japanese only)

Ethical Considerations in Animal Experimentation

In order to verify safety and efficacy in the process of creating new drugs, it is imperative that animal testing be conducted in compliance with all laws. At Sumitomo Dainippon Pharma, we believe that the animal testing process must be based on scientific rationale, and we make every effort to ensure that all testing is carried out with consideration of animal welfare and respect for animal life.

In animal experimentation, Sumitomo Pharma follows in-house procedures that conform to Japan's Act on Welfare and Management of Animals and the Basic Policies for the Conduct of Animal Experiments in Research Institutions under jurisdiction of the Ministry of Health, Labour and Welfare. Our Institutional Animal Care and Use Committee strictly reviews all experimental protocols, including outsourced tests, in terms of the "4Rs" (adding an additional "R" for the "responsibility" of those carrying out and commissioning the testing to the conventional "reduction" of the number of animals used, "replacement" with alternative testing methods, and "refinement" to relieve pain and distress). As part of our efforts to maintain and improve the ethical and scientific integrity of our animal experimentation, we also continually implement in-house inspection and assessment of the animal testing process.

Sumitomo Pharma has earned the Center for Accreditation of Laboratory Animal Care and Use (CALAC)* accreditation as an animal testing facility in compliance with the basic policies of the Ministry of Health, Labour and Welfare. CALAC, an arm of the Japan Health Sciences Foundation, evaluates animal testing research institutions under the jurisdiction of the Ministry for appropriate conduct in line with the Ministry's basic policies.

* CALAC is an organization within the Japan Health Sciences Foundation that conducts third-party inspections and evaluations of animal experimentation and other work at animal testing research institutions under the jurisdiction of the Ministry of Health, Labour and Welfare. CALAC determines whether such facilities are conducting appropriate experiments based on a scientific perspective, while promoting voluntary ethics management of animal testing programs and considerations of animal welfare.

(2) Development

(3) Procurement

Ethics in Procurement

1Balanced and fair transactions with our business partners
  • We will enter into and maintain transparent transactions, while striving to always create business opportunities with new business partners based on balanced, fair and free competition.
  • We will enter into transactions by observing mutual benefit and establishing trustful relationships.
2Reasonable selection of suppliers
  • In the selecting suppliers, we will base determinations on economic rationality, with comprehensive consideration of suppliers' management base stability, quality, price, supply stability, technical development, environmental stance, etc.
  • We will not enter into a reciprocal transaction for the direct purpose of selling Sumitomo Dainippon Pharma's products and services.
3Mutual evolution
  • Through sound transactions with business partners, we will strive for mutual evolution while deepening mutual understanding.
4Thorough compliance with laws and regulations and protection of confidentiality
  • We will prevent the illegal acquisition or leaking of confidential and proprietary information of Sumitomo Pharma and business partners, while complying with not only relevant law, rules and regulations but also the letter and spirit of these laws and regulations.

(4) The Environment

(5) Safety and Health

Basic Safety and Health Policy

Sumitomo Pharma will ensure that workplace environments are safe and comfortable for individual employees to work in so that all directors and employees can have peace of mind and concentrate on their work, allowing them to maximize their autonomy and creativity. In all of our business activities, we will pursue safety and health companywide and seek to ensure the safety of our employees and promote and maintain their health. We will also work to ensure the safety and health of the communities in which we operate and all outside parties in our workplaces.

  • ① While continuing to strive to conduct business activities free from accidents and disasters, we will ensure the safety of our employees.
  • ② In addition to abiding by laws, regulations and other requirements for occupational safety and health, we will make continuous efforts to improve our standards of safety and health management.
  • ③ Through education and activities that raise awareness about safety and health, we will seek to improve the safety and health awareness of all employees.
  • ④ We will work to help employees maintain physical and mental health and to create workplace environments where people can work with peace of mind.

(6) Corporate Citizenship Activities

Basic Stance on Social Contribution Activities

In its Declaration of Conduct, Sumitomo Pharma declares its intent to "7. Build harmonious relationships with society," and we engage in social contribution activities befitting a good corporate citizen.

Focusing on activities related to our business including raising awareness of diseases and educational support, environmental conservation activities, and donations/supportive activities, we have identified the following pivotal action items as our basic stance on social contribution activities we promote to fulfil our corporate citizenship.

  • Ensure that our employees always have an awareness that our business is dependent on public trust and credibility
  • Respect and understand diverse values and cultures nurtured in various communities and by people
  • Be aware of harmonious relationships with society and fulfill responsibilities as well as contributions as a member of society

We have further established systems that allow each employee to better take part in philanthropic activities.

(7) Compliance

■ Global Quality Policy (Sumitomo Pharma Group Quality Policy)

Sumitomo Pharma Co., Ltd. and all of Sumitomo Pharma's affiliates and subsidiaries worldwide who signed below (collectively the "Sumitomo Pharma Group Companies"), are fully committed to quality assurance as a primary objective in all aspects of operation. As responsible pharmaceutical companies, we, the Sumitomo Pharma Group Companies, shall work to produce and supply customers with high-quality products.

  1. We, the Sumitomo Pharma Group Companies, shall provide satisfactory quality products to customers based upon consistent monitoring of customer needs.
  2. We, the Sumitomo Pharma Group Companies, shall develop and apply practices leading to high-quality products, beginning with the start of product development and continuing throughout all stages of production and commercialization.
  3. We, the Sumitomo Pharma Group Companies, shall establish and maintain a consistent quality system for all phases of operation from procurement of raw materials through product manufacturing, distribution, and sales.
  4. We, the Sumitomo Pharma Group Companies, shall act in accordance with the relevant legal and regulatory requirements, and establish and comply with quality standards at the global level based on current scientific and technological knowledge.
  5. We, the Sumitomo Pharma Group Companies, shall have all our executives and employees involved in quality raise and strive to retain a high level of awareness and knowledge on the quality.